Meadowhawk Biolabs has filed a notice of an exempt offering of securities to raise $6,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Meadowhawk Biolabs is raising $6,000,000.00 in new funding. Sources indicate that as part of senior management Senior Executive, Peter Glick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Meadowhawk Biolabs
Meadowhawk biolabs is a CRO that was created to make a difference for our pharmaceutical and biotech clients in drug discovery and development. Our curiosity, unwillingness to accept the status quo and unflagging commitment and alignment to our values drives us to partner with our clients to bring new treatments and therapeutics faster to patients.
To learn more about Meadowhawk Biolabs, visit http://www.meadowhawkbiolabs.com/
Contact:
Peter Glick, Senior Executive
617-798-6181
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.